SMT201700072B - Utilizzo del pidotimod per il trattamento della psoriasi - Google Patents
Utilizzo del pidotimod per il trattamento della psoriasiInfo
- Publication number
- SMT201700072B SMT201700072B SM201700072T SM201700072T SMT201700072B SM T201700072 B SMT201700072 B SM T201700072B SM 201700072 T SM201700072 T SM 201700072T SM 201700072 T SM201700072 T SM 201700072T SM T201700072 B SMT201700072 B SM T201700072B
- Authority
- SM
- San Marino
- Prior art keywords
- pidotimod
- psoriasis
- treatment
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title 1
- 201000004681 Psoriasis Diseases 0.000 title 1
- 229960001163 pidotimod Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12812221.5A EP2934521B1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
| PCT/EP2012/076088 WO2014094840A1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201700072B true SMT201700072B (it) | 2017-03-08 |
Family
ID=47520054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20170072T SMT201700072T1 (it) | 2012-12-19 | 2012-12-19 | Utilizzo del pidotimod per il trattamento della psoriasi |
| SM201700072T SMT201700072B (it) | 2012-12-19 | 2017-01-30 | Utilizzo del pidotimod per il trattamento della psoriasi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20170072T SMT201700072T1 (it) | 2012-12-19 | 2012-12-19 | Utilizzo del pidotimod per il trattamento della psoriasi |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (it) |
| EP (1) | EP2934521B1 (it) |
| JP (1) | JP6051315B2 (it) |
| KR (1) | KR20150095773A (it) |
| CN (1) | CN104869994B (it) |
| AR (1) | AR094027A1 (it) |
| AU (1) | AU2012396942A1 (it) |
| BR (1) | BR112015011391A2 (it) |
| CA (1) | CA2887878A1 (it) |
| CY (1) | CY1118645T1 (it) |
| DK (1) | DK2934521T3 (it) |
| EA (1) | EA201591185A1 (it) |
| ES (1) | ES2617235T3 (it) |
| HK (1) | HK1210937A1 (it) |
| HR (1) | HRP20161666T1 (it) |
| HU (1) | HUE031846T2 (it) |
| IL (1) | IL239429A0 (it) |
| LT (1) | LT2934521T (it) |
| MA (1) | MA38155B1 (it) |
| ME (1) | ME02560B (it) |
| MX (1) | MX2015008104A (it) |
| PH (1) | PH12015501210A1 (it) |
| PL (1) | PL2934521T3 (it) |
| PT (1) | PT2934521T (it) |
| RS (1) | RS55436B1 (it) |
| SG (1) | SG11201503270UA (it) |
| SI (1) | SI2934521T1 (it) |
| SM (2) | SMT201700072T1 (it) |
| TN (1) | TN2015000142A1 (it) |
| WO (1) | WO2014094840A1 (it) |
| ZA (1) | ZA201502573B (it) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (en) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod for use in the treatment of inflammation-associated diseases |
| MA44510A (fr) * | 2016-03-29 | 2021-03-31 | Janssen Biotech Inc | Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23 |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase |
-
2012
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 HK HK15111635.1A patent/HK1210937A1/xx unknown
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 SM SM20170072T patent/SMT201700072T1/it unknown
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 HR HRP20161666TT patent/HRP20161666T1/hr unknown
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 CA CA2887878A patent/CA2887878A1/en not_active Abandoned
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/en not_active Ceased
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Withdrawn
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/me unknown
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/en active Active
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283943A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
| LT2885010T (lt) | Tautopatijos gydymo būdai | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| ZA201604110B (en) | New treatment of chronic ulcers | |
| EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
| LT2981255T (lt) | Empagliflozino terapiniai panaudojimo būdai | |
| EP2968208A4 (en) | TREATMENT OF CATAPLEXIA | |
| EP2920308A4 (en) | CANCER TREATMENT | |
| HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
| PT3626270T (pt) | Tratamento de doenças cardiovasculares | |
| LT2928477T (lt) | Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui | |
| PL2839230T3 (pl) | Instalacja do obróbki obiektów | |
| SMT201500057B (it) | Uso della biotina per il trattamento della sclerosi multipla | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| EP2830633A4 (en) | COMBINATION THERAPY FOR CANCER TREATMENT | |
| EP2869833A4 (en) | TREATMENT OF INFLAMMATORY SKIN DISORDERS | |
| EP2817011A4 (en) | CANCER TREATMENT | |
| HRP20180670T1 (hr) | Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka | |
| LT2914254T (lt) | Kombinacinės terapijos chemoresistencinių vėžių gydymui | |
| HUE045445T2 (hu) | Kombinált terápia petefészekrák kezelésére | |
| HUE045947T2 (hu) | Formuláció IBS kezelésére | |
| PL2831110T3 (pl) | Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych | |
| IL242220A0 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| SMT201700072B (it) | Utilizzo del pidotimod per il trattamento della psoriasi |